

# Index

## Number and Symbols

- 2D in vitro liver cell cultures, 53–54
  - primary cell cultures, 51
  - sandwich-cultured hepatocytes, 47, 52
  - shortcomings of, 53
- 3D in vitro liver models
  - multicellular tumor spheroid, 55
  - organ-in-a-chip, 55–56, 61
  - organoid-on-chip systems, 61
  - organoids, 56–57, 59
  - overview, 53
  - precision-cut tissue slices (PCTS)
    - (*see* precision-cut tissue slices (PCTS))
  - tumor organoids, 59–60
  - tumor tissue explants, 54–55
  - whole organ explants, 53
- 5-Fluoracil, 142

## A

- ABCG2, 15, 16*t*, 17
- Absorption, distribution, metabolism, excretion, and toxicity (ADMET) screening, 49–50
- Aflatoxin B1, 2, 96
- Alcohol abuse, 2, 33, 96. *See also* cirrhosis; hepatocellular carcinoma (HCC)
- Alpha-1 antitrypsin (A1AT)-deficiency, 56
- Alpha-fetoprotein (AFP), 10, 82
- American Lifestyle-Induced Obesity Syndrome (ALIOS) model, 79
- Apolipoprotein A-IV, 98
- ARID1A, 2
- ARID2, 2

- Associating liver partition, and portal vein ligation for staged hepatectomy (ALPPS) procedure, 112, 118
- ATP-binding cassette subfamily B member 1 (ABCB-1), 142
- Aurora A kinase (AURKA), 2
- Autophagy, 148

## B

- Barcelona Clinic Liver Cancer algorithm (BCLC), 111, 112, 113–114, 115–116, 117, 119, 128, 131, 133
- B-catenin, 6
- Biliary epithelial cells, 36, 48
- BMI-1, 36

## C

- Cabozantinib, 133–135
- Cancer stem cells (CSCs), 1
  - angiogenesis, 36–37
  - assays, 3
  - characteristics of, 8, 15
  - concept of, overview, 7–8, 147–148
  - differentiation, 17
  - HCC environment, as part of, 39
  - liver cancer stem cells (LCSCs) (*see* liver cancer stem cells (LCSCs))
  - markers, 19 (*see also* *specific markers*)
  - multidrug resistance, 147–148
  - origin, 2
  - proliferation, 150
  - regulation of, 9
  - resistance, multidrug, 33
  - self-renewal of, 19

treatment of, 16  
 tumor recurrence,  
     post-chemotherapy, 15  
 tumor-initiating cells, 33  
 Carbon tetrachloride (CCl<sub>4</sub>), 75–76  
 Catenin beta 1 (CTNNB1), 2  
 CD105, 34  
 CD13, 10, 15, 17, 34  
 CD133, 6, 7, 8, 9, 10, 11, 12, 15, 16, 17,  
     34, 36, 39, 147, 150  
 CD24, 9, 10, 11, 12, 15, 147  
 CD44, 6, 9, 10, 11, 16, 17, 32, 34, 35, 36,  
     38, 39, 147  
 CD45, 10, 34, 35  
 CD90, 10, 11, 15, 34, 36  
 CELESTIAL trial, 115, 129*t*, 134  
 Cell of origin, 1, 2, 3, 4, 5*t*, 6, 7, 14, 18  
 Chemotherapy resistance, 9  
 Cirrhosis, 8, 32, 35, 36, 70, 75, 76, 96,  
     97–98, 100, 104, 113, 114, 116,  
     128, 132, 134, 135, 136  
 Cisplatin, 18, 142, 144, 145, 146, 147,  
     150, 152  
 Cre-Lox, 83  
 CRISPR, 51, 57, 83, 85  
 CTGF-β, 36  
 CYP3A4, 52  
 Cystic fibrosis transmembrane  
     conductance regulator (CFTR), 57  
 Cytochrome P450 (CYP450), 48, 51, 52,  
     53, 54, 56, 57, 61, 75, 145  
 Cytokeratin (CK) 19, 6, 82  
 Cytokines, 33

## D

*De novo* lipogenesis, 98  
 Decorin, 36, 38, 39  
 Dendritic cells, 32

Diarrhea, side effect of treatment, 136  
 Diet-induced Animal Model Of Non-  
     alcoholic fatty liver Disease  
     (DIAMOND), 79–80  
 Diethylnitrosamine (DEN), 74–75  
 Doxorubicin, 142

## E

Eastern Cooperative Oncology Group  
     performance status (ECOG), 128  
 Ectopic lymphoid structures (ELS), 8  
 EGF, 38  
 Eosinophils, 32  
 Epidermal growth factor receptor (EGFR),  
     12, 13, 39, 130  
 Epithelial cell adhesion molecule  
     (EpCAM), 6, 7, 9, 10, 11, 17,  
     34, 36, 82  
 Epithelial-mesenchymal transition (EMT),  
     11, 12, 13, 37, 38, 144  
 Extracellular matrix (ECM), 30  
     abnormal, 32  
     cell function, relationship to, 51  
     changes in, 35  
     components of, 31–32  
     embryonic development, composition  
         of during, 31  
     organ homeostasis, composition of  
         during, 31  
     remodeling, 32, 38  
     in vitro models, in, 50  
 Extracellular signal-regulated kinases  
     (ERK), 55

## F

Fatty acid metabolism, 95, 99  
 Fatty acid-binding protein (FABP), 98

Fibroblasts, 48

FOLFOX, 128

Forkhead box L1 (Foxl1)+ cells, 7

## H

Ha-rat sarcoma (Ras), 6

Hand-foot syndrome, 127, 135

Hedgehog, 36

Hemochromatosis, 96

Heparin sulfate (HS), 36

Hepatic progenitor cells (HPCs), 7

carcinogenesis, 18

cell of origin, HCC, 5*t*, 7

cholangiocyte cell line, 12

EpCAM, relationship between, 10, 11

limitations, 15

malignant transformation, 3, 6

markers, 6

neoplastic transformation, 4

OV6, relationship between, 11

tracking, 7

tumor heterogeneity, 8

Hepatic stellate cells (HSCs), 31, 32, 35,

36, 39, 48, 100

Hepatitis B, 2, 32, 33, 35, 52,

77, 97, 98

Hepatitis C, 2, 33, 97

Hepatocellular carcinoma (HCC)

angiogenesis, 38

causes of, 30, 33

cellular morphology, 3, 36

cellular origins, 3, 5*t*, 6–7

CSC population, 33

deaths attributed to, 70

diagnosis, 2, 18

genetic alterations, 2, 100

genetic factors, 83

growth, 32

inflammation causes, 30, 33–34

inflammation, links to, 35, 37–38

markers, 11, 33–34, 36

metastasis, 101

molecular features, 1, 2, 3

mortality, 127, 142

mouse models (*see* mouse  
models, HCC)

multidrug resistance (*see* multidrug  
resistance, HCC)

overview, 70–71, 95, 96–97, 142

progenitor cells, 3–4

prognosis, 18

progression, 38, 97–98

proliferation, 37

risk factors, 2

staging, 113–114, 115–116

stem cell self-renewal, 9

surgical techniques (*see* surgical  
techniques, HCC)

therapeutic options, 2, 15

treatment, improving, 18

tumor microenvironment, 29–30,  
30–31

worldwide rates of, 70, 95

zonation, relationship between, 49

Hepatocyte growth factor (HGF), 9,  
73*t*, 81

Hepatocyte nuclear factor (HNF), 7, 18

Hepatocytes, 2

HepG2, 38, 50, 52, 56, 143, 147, 1  
50, 151

HepG2/C3a cells, 56

HepRG, 52, 61

Hippo signaling, 4

Human genome project, 50

Hyaluronic acid (HA), 32, 35, 38, 39

Hypertension, side effect of treatment, 136

H $\mu$ Rel, 55

**I**

IL-6, 3, 7, 8, 9, 13, 17, 35, 38, 39  
IL-8, 9, 38

**K**

Krebs cycle, 99  
Kupffer cells, 33, 35, 48, 57, 75

**L**

Laparoscopic liver resection (LLR), 112, 117  
Lenvatinib, 115, 127, 131–132, 133, 135, 136, 137  
Lin28, 36  
Lipid metabolic reprogramming, 99–100, 102–104  
Lipidomics, 100–101  
Liver cancer. *See* Hepatocellular carcinoma (HCC)  
Liver cancer stem cells (LCSCs)  
  characterization of, 14–15  
  diversity of, 13  
  hepatocarcinogenesis, role in, 8  
  identifying, 13  
  importance of in HCC treatment, 17  
  isolation of, 13  
  malignant transformation of, 12  
  markers, 8–11, 17 (*see also specific markers*)  
  signaling pathways, 12–13  
  therapeutic resistance of, 15–16  
Liver progenitor cells (LPCs), 34–35, 36, 39, 82  
Liver regeneration, 98  
Liver sinusoidal endothelial cells (LSECs), 48, 60

Liver transplant, 2  
Liver-on-chip technology, 47, 55, 56, 60  
Liver, in vitro models of, 47  
  2D in vitro liver cell cultures (*see* 2D in vitro liver cultures)  
  3D in vitro liver models (*see* 3D in vitro liver models)  
  defining, 48  
  drug development, importance to, 49–50, 57, 59  
  future directions in, 60–61  
  immortalized cell lines, 52  
  improving, 48  
  lobules, 48–49, 53  
  organotypic cultures, 52–53  
  precision medicine, 50, 53

**M**

Macrophages, 9, 30, 33, 38, 48, 53  
Mapk14, 2  
Mechanistic target of rapamycin (mTORC), 7  
Melanoma, 74  
Mesenchymal stem/stromal cells (MSCs), 3, 9, 10, 11, 30, 36, 37, 103t  
Metallothionein, 144–145  
Metastasis, 9, 32, 101  
Metformin, 100, 104  
MHCC97H, 38  
Microliver chip, 55  
MiR-181, 36  
MMP-2, 38  
MMP-9, 38  
Model of end-stage liver disease (MELD), 118  
Mouse models, HCC  
  c-Myc, 81

- choline-deficient and ethionine-supplemented (CDE) diet, 76, 79
  - diet-induced models, 77, 79
  - hepatotoxins used, 71, 74 (*see also specific toxins*)
  - hydrodynamic tail vein injection (HTVI) models, 82–85
  - liver-specific knockout model, 82
  - overview, 69–70
  - Wnt/ $\beta$ -catenin model, 81–82
- MRECIST, 133
- Multidrug resistance, HCC
- apoptosis, 145, 146–147
  - autophagy, 148
  - cancer stem cells (CSCs), 147–148
  - cellular metabolism, 145
  - drug sequestration, 144–145
  - enhanced drug delivery, 149–150
  - enhanced drug efflux, 142–144
  - modulators/chemosensitizers, 148–149
  - natural products to address, 150–152
  - non-coding RNAs (ncRNAs) (*see non-coding RNAs (ncRNAs)*)
  - overview, 141, 142
  - reduced drug uptake, 144
  - RNA interference (RNAi) (*see RNA interference (RNAi)*)
  - tumor microenvironment, 147
- N**
- Nanog, 8, 9, 13, 16*t*
- Nanotechnology, 149
- National Comprehensive Cancer Network (NCCN), 132
- Natural killer (NK) cells, 32
- Nestin, 8
- Neurofibromatosis type 2 (Nf2), 6
- Neutrophils, 32
- Non-alcoholic fatty liver disease (NAFLD), 49, 77, 97, 104
- Non-alcoholic steatohepatitis (NASH), 33, 77, 79, 83, 97, 100, 104
- Non-coding RNAs (ncRNAs), 145–146
- Notch signaling, 5*t*, 6, 12, 13, 36, 56, 147, 151
- O**
- Oct4, 11, 13, 15
- Oncogenesis, 1
- Oncostatin M (OSM), 17
- Organoid-on-chip systems, 61
- Organotypic cultures, 47, 48, 52–53, 55, 57
- Osteopontin (Opn)-CreERT2, 7
- OV6, 11
- P**
- P53 tumor suppressor, 3
- Phosphatase and tensin homolog (PTEN), 82
- Polyethylene glycol (PEG), 149
- Polyethylenimine (PEI), 149
- Precision medicine, 50, 53
- Precision-cut tissue slices (PCTS), 47, 54
- Proteoglycans (PGs), 32, 36, 38, 39
- R**
- Radiofrequency ablation (RFA), 2
- REFLECT study, 132
- Regorafenib, 133–134

Regulatory T cells (Tregs), 33  
 RESORCE study, 133  
 RNA interference (RNAi), 150, 152  
 RNAi screening, 2  
 Robot-assisted liver resection (RALR),  
 112, 117–118

## S

Sandwich-cultured hepatocytes, 47, 52  
 Signal transducer and activator of  
 transcription (STAT), 6  
 Sleeping beauty (SB) transposase, 83  
 Small leucine-rich proteoglycan (SLRP), 36  
 Small leucine-rich proteoglycan (SLRP)  
 gene family, 36  
 Sonic hedgehog (Shh) pathway, 12  
 Sorafenib, 127, 129*t*  
 advanced-stage disease, use in, 115  
 approval, 130  
 clinical trials, 38, 60, 130–131, 135  
 dosage, 132  
 drug delivery, enhanced, 149, 151  
 FDA approval, 130  
 hand-foot syndrome in patients treated  
 with, 135  
 metabolism of, 145  
 overview, 130–131  
 resistance to, 143–144, 146, 147, 148,  
 149  
 response, in HCC patients, 15, 85, 115,  
 131, 132, 133, 134, 137, 142,  
 149, 152  
 sequestration of, 144–145  
 SHARP study, 130  
 side effects, 136  
 survival benefits, 127  
 therapeutic resistance, 16, 16*t*  
 tolerance of, 133

treatment, 2, 115  
 tumor microenvironment, 147  
 uptake of, 144  
 usage, 131  
 in vitro activity, 60

SOX2, 13  
 SOX9, 6, 7  
 STAT3, 13  
 Statins, 100, 104  
 Sterol regulatory element-binding proteins  
 (SREBP), 80, 99, 102, 103  
 Surgical techniques, HCC  
 associating liver partition, and portal  
 vein ligation for staged  
 hepatectomy (ALPPS)  
 procedure (*see* associating liver  
 partition, and portal vein  
 ligation for staged hepatectomy  
 (ALPPS) procedure)  
 laparoscopic liver resection (LLR) (*see*  
 laparoscopic liver resection  
 (LLR))  
 limitations of, 116  
 overview, 111, 112  
 preoperative assessment, 112–113  
 resection, 112  
 robot-assisted liver resection (RALR)  
 (*see* robot-assisted liver  
 resection (RALR))  
 transplant, 112, 116, 119  
 Syndecan-1, 36

## T

T cells, 33  
 TAP1, 142  
 Telomerase reverse transcriptase  
 (TERT), 2  
 TGF $\beta$ , 38

- Thioacetamide (TAA), 75, 76–77
- TNF $\alpha$ , 38
- TP53 gene, 2, 82
- Transarterial chemoembolization (TACE), 2
- Transforming growth factor beta (TGF $\beta$ ), 4, 12, 13
- Transforming growth factor beta 1 (TGF-b1), 36
- Tumor microenvironment (TME)  
biology of tumor, 30  
cells in, 32  
complexity of, 30  
composition of, 30–31  
generation of, 32  
inflammatory cells in, 35  
interactions with tumor, 30  
multidrug resistance, role in, 147  
regulators of tumor process, 32
- Tumor-associated fibroblasts (TAFs), 30
- Tumor-associated macrophages (TAMs), 30, 35  
targeted therapies, 38
- Tumor-initiating cells (TICs), 1, 2, 3–4, 10, 11, 13, 15, 17, 33
- Tumorigenicity, 9
- Tyrosine kinases inhibitors, 39  
cabozantinib (*see* cabozantinib)  
combination therapies, 137  
diarrhea, side effect, 136  
fatigue, side effect, 136  
hand-foot disease, as side effect (*see* hand-foot syndrome)  
hypertension, side effect, 136  
lenvatinib (*see* lenvatinib)  
nausea/vomiting, side effect, 136  
overview, 127, 128  
regorafenib (*see* regorafenib)  
sorafenib (*see* sorafenib)  
tolerance of, 136–137
- V**
- Vascular endothelial growth factor A (VEGFA) gene  
amplification, 129
- VEGF, 38, 129, 133
- Very long chain fatty acids (VLCFAs), 100, 101
- W**
- Warburg effect, 99
- Whole-exome sequencing (WES), 59
- Wilson's disease, 96
- Wnt pathway, 6, 37
- Wnt/ $\beta$ -catenin, 12, 36
- Y**
- Yes-associated protein (YAP), 4
- Z**
- Zyoxel, 55